Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington’s disease: an update

References

• Dash D, Mestre TA. therapeutic update on huntington’s disease: symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics. 2020;17:1645–1659.
   PubMed Web of Science ®Google Scholar
• Schneider F, Stamler D, Bradbury, et al. Pharmacokinetics of deutetrabenazine and tetrabenazine: dose proportionality and food effect. Clin Pharmacol Drug Dev. 2021;10(6):647–659.
   PubMed Web of Science ®Google Scholar
• Claassen DO, Philbin M, Carroll B. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington’s disease: a review of clinical trial data. Expert Opin Pharmacother. 2019;20(18):2209–2221.
   PubMed Web of Science ®Google Scholar
• Rodrigues FB, Duarte GS, Costa J, et al. Tetrabenazine versus deutetrabenazine for Huntington’s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4(4):582–585.
   PubMed Web of Science ®Google Scholar
• Stahl CM, Feigin A. Medical, surgical, and genetic treatment of huntington disease. Neurol Clin. 2020;38:367–378.
   PubMed Web of Science ®Google Scholar
• Biolsi B, Cif L, Fertit HE, et al. Long-term follow-up of Huntington disease treated by bilateral deep brain stimulation of the internal globus pallidus. J Neurosurg. 2008;109:130–132.
   PubMed Web of Science ®Google Scholar
• Cislaghi G, Capiluppi E, Saleh C, et al. Bilateral globus pallidus stimulation in Westphal variant of huntington disease. Neuromodulation. 2014;17:502–505.
   PubMed Web of Science ®Google Scholar
• Fasano A, Mazzone P, Piano C, et al. GPi-DBS in Huntington’s disease: results on motor function and cognition in a 72-year-old case. Mov Disord. 2008;23:1289–1292.
   PubMed Web of Science ®Google Scholar
• Ferrea S, Groiss SJ, Elben S, et al. Pallidal deep brain stimulation in juvenile Huntington’s disease: local field potential oscillations and clinical data. J Neurol. 2018;265:1573–1579.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Ayerbe J, Del Val J, et al. Deep brain stimulation in disabling involuntary vocalization associated with Huntington’s disease. Parkinsonism Relat Disord. 2012;18:803–804.
   PubMed Web of Science ®Google Scholar
• Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington’s disease: long-term results of a prospective open-label study. J Neurosurg. 2014;121:114–122.
   PubMed Web of Science ®Google Scholar
• Gruber D, Kuhn AA, Schoenecker T T, et al. Quadruple deep brain stimulation in Huntington’s disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. J Neural Transm (Vienna). 2014;121:1303–1312.
   PubMed Web of Science ®Google Scholar
• Habets JGV, Heijmans M, Kuijf ML, et al. An update on adaptive deep brain stimulation in Parkinson’s disease. Mov Disord. 2018;33:1834–1843.
   PubMed Web of Science ®Google Scholar
• Hebb MO, Garcia R, Gaudet P, et al. Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington’s disease: technical case report. Neurosurgery. 2006 discussion E83;58:E383.
   PubMedGoogle Scholar
• Huys D, Bartsch C, Poppe P, et al. Management and outcome of pallidal deep brain stimulation in severe Huntington’s disease. Fortschr Neurol Psychiatr. 2013;81:202–205.
   PubMed Web of Science ®Google Scholar
• Kang GA, Heath S, Rothlind J, et al. Long-term follow-up of pallidal deep brain stimulation in two cases of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2011;82:272–277.
   PubMed Web of Science ®Google Scholar
• Moreno JL L-S, Garcia-Caldentey J, Regidor I, et al. A 5-year follow-up of deep brain stimulation in Huntington’s disease. Parkinsonism Relat Disord. 2014;20:260–261.
   PubMed Web of Science ®Google Scholar
• Mitchell KT, Ostrem JL. Surgical treatment of parkinson disease. Neurol Clin. 2020;38:293–307.
   PubMed Web of Science ®Google Scholar
• Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington’s disease. Ann Neurol. 2004;56:290–294.
   PubMed Web of Science ®Google Scholar
• Sanrey E, Macioce V, Gonzalez V, et al. Does pallidal neuromodulation influence cognitive decline in Huntington’s disease? J Neurol. 2021;268:613–622.
   PubMed Web of Science ®Google Scholar
• Spielberger S, Hotter A, Wolf E, et al. Deep brain stimulation in Huntington’s disease: a 4-year follow-up case report. Mov Disord. 2012 author reply 07-8;27:806–807.
   PubMed Web of Science ®Google Scholar
• Vedam-Mai V, Martinez-Ramirez D, Hilliard JD, et al. Post-mortem findings in huntington’s deep brain stimulation: a moving target due to atrophy. Tremor Other Hyperkinet Mov (N Y). 2016;6:372.
   PubMedGoogle Scholar
• Velez-Lago FM, Thompson A, Oyama G, et al. Differential and better response to deep brain stimulation of chorea compared to dystonia in Huntington’s disease. Stereotact Funct Neurosurg. 2013;91:129–133.
   PubMed Web of Science ®Google Scholar
• Wojtecki L, Groiss SJ, Ferrea S, et al. A prospective pilot trial for pallidal deep brain stimulation in Huntington’s disease. Front Neurol. 2015;6:177.
   PubMed Web of Science ®Google Scholar
• Zittel S, Tadic V, Moll CKE, et al. Prospective evaluation of Globus pallidus internus deep brain stimulation in Huntington’s disease. Parkinsonism Relat Disord. 2018;8; 51:96–100.
   Web of Science ®Google Scholar
• Young CB, Reddy V, Sonne JN. Basal Ganglia. in, StatPearls 2021 (Treasure Island (FL)).
   Google Scholar
• Yin Z, Bai Y, Zhang H, et al. An individual patient analysis of the efficacy of using GPi-DBS to treat Huntington’s disease. Brain Stimul. 2021;13:1722–1731.
   Web of Science ®Google Scholar
• Sharma M, Deogaonkar M. Deep brain stimulation in Huntington’s disease: assessment of potential targets. J Clin Neurosci. 2015;22:812–817.
   PubMed Web of Science ®Google Scholar
• Delorme C, Rogers A, Lau B, et al. Deep brain stimulation of the internal pallidum in Huntington’s disease patients: clinical outcome and neuronal firing patterns. J Neurol. 2016;263:290–298.
   PubMed Web of Science ®Google Scholar
• Hariz MI, Blomstedt P, Zrinzo L. Deep brain stimulation between 1947 and 1987: the untold story. Neurosurg Focus. 2010;29(2):E1. FOCUS10106.
   PubMed Web of Science ®Google Scholar
• Wong JK, Middlebrooks EH, Grewal SS, et al. A comprehensive review of brain connectomics and imaging to improve deep brain stimulation outcomes. Mov Disord. 2020;35(5):741–751.
   PubMed Web of Science ®Google Scholar
• Horn A, Fox MD. Opportunities of connectomic neuromodulation. Neuroimage. 2020;221:117180.
   PubMed Web of Science ®Google Scholar
• Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5(2):181–197.
   PubMed Web of Science ®Google Scholar
• Gögel S, Gubernator M, Minger SL. Progress and prospects: stem cells and neurological diseases. Gene Ther. 2011;18(1):1–6.
   PubMed Web of Science ®Google Scholar
• Krystkowiak P, Gaura V, Labalette M, et al. Alloimmunization to donor antigens and immune rejection following foetal neural grafts to the brain in patients with Huntington’s disease. PLoS One. 2007;1:e166.
   Google Scholar
• Keene CD, Sonnen JA, Swanson PD, et al. Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology. 2007;68:2093–2098.
   PubMed Web of Science ®Google Scholar
• Keene CD, Chang RC, Leverenz JB, et al. A patient with Huntington’s disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol. 2009;117:329–338.
   PubMed Web of Science ®Google Scholar
• Reuter I, Tai YF, Pavese N, et al. Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington’s disease. J Neurol Neurosurg Psychiatry. 2008;79:948–951.
   PubMed Web of Science ®Google Scholar
• Capetian P, Knoth R, Maciaczyk J, et al. Histological findings on fetal striatal grafts in a Huntington’s disease patient early after transplantation. Neuroscience. 2009;160:661–675.
   PubMed Web of Science ®Google Scholar
• Cicchetti F, Saporta S, Hauser RA, et al. Neural transplants in patients with Huntington’s disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci. 2009;106(30):12483–12488.
   PubMed Web of Science ®Google Scholar
• Bachoud-Lévi AC. From open to large-scale randomized cell transplantation trials in Huntington’s disease: lessons from the multicentric intracerebral grafting in Huntington’s disease trial (MIG-HD) and previous pilot studies. Prog Brain Res. 2017;230:227–261.
   PubMed Web of Science ®Google Scholar
• Bachoud-Lévi AC, Rémy P, Nguyen JP, et al. Motor and cognitive improvements in patients with Huntington’s disease after neural transplantation. Lancet. 2000;356:1975–1979.
   PubMed Web of Science ®Google Scholar
• Bachoud-Lévi AC, Gaura V, Brugières P, et al. Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol. 2006;5:303–309.
   PubMed Web of Science ®Google Scholar
• Bachoud-Lévi AC, Schramm C, Remy P. On behalf the multicentric intracerebral grafting in huntington’s disease group. human fetal cell therapy in Huntington’s disease: a randomized, multicenter, phase ii trial. Mov Disord. 2020;35(8):1323–1335.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in huntington’s disease. Neuron. 2019;101(5):801–819.
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci. 2005;102:5820–5825.
   PubMed Web of Science ®Google Scholar
• Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther. 2008;16:947–956.
   PubMed Web of Science ®Google Scholar
• McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther. 2011;19:2152–2162.
   PubMed Web of Science ®Google Scholar
• Miniarikova J, Zanella I, Huseinovic A, et al. Design, characterization, and lead selection of therapeutic miRNAs targeting Huntingtin for development of gene therapy for Huntington’s disease. Mol Ther Nucleic Acids. 2016;5:e297.
   PubMedGoogle Scholar
• Evers MM, Miniarikova J, Juhas S, et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington’s disease minipig model. Mol Ther. 2018;26:2163–2177.
   PubMed Web of Science ®Google Scholar
• Ajitkumar A. De Jesus O. Huntington disease. in statpearls 2021 (Treasure Island (FL)
   Google Scholar
• Caron NS, Wright GEB, Hayden MR. Huntington Disease. In: Adam MP, Ardinger HH, Pagon RA, et al., editors GeneReviews® [Internet]. Seattle (WA): University of Washington; 1993–2022. p.1–34. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1305/.
   Google Scholar
• Chen W, Hu Y, Ju D. Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B. 2020;10:1347–1359.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Flower MD, Ross CA, et al. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16:529–546.
   PubMed Web of Science ®Google Scholar
• Drew CJG, Sharouf F, Randell E, et al. Protocol for an open-label phase 1 trial within a cohort of foetal cell transplants in people with Huntington`s disease. Brain Comm. 2021;3(1):fcaa320.
   Google Scholar
• Maxan A, Mason S, Saint-Pierre M, et al. Outcome of cell suspension allografts in a patient with Huntington’s disease. Ann Neurol. 2018;84(6):950–956.
   PubMed Web of Science ®Google Scholar
• Cicchetti F, Lacroix S, Cisbani G, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76(1):31–42.
   PubMed Web of Science ®Google Scholar
• Cisbani C, Maxan A, Kordower JH, et al. Presence of tau pathology within foetal neural allografts in patients with Huntington`s and Parkinson´s disease. Brain. 2017;140:2982–2992.
   PubMedGoogle Scholar